Indian firm eyes global egg yolk powder sales after moving to new GMP-compliant site
The ingredient was created in 2013, but the firm's previous site was not GMP-compliant.
"We have recently commissioned our new facility in early 2017, after which Lipova was launched commercially," said Vrushali Patil, assistant manager for international business.
Lipova-E100 is a natural mixture of egg phospholipids and proteins, produced via a selective extraction of hen egg yolk after the removal of neutral oils (triglycerides) and cholesterol.
According to the firm, the product retains all the health benefits of egg phospholipids, proteins, and omega-3 and omega-6 fatty acids; it is suitable for use in supplements and infant formula.
Lipova E-200, meanwhile, is a natural concentrate of purified egg yolk proteins for use in sports nutrition products, functional foods and beverages, and supplements.
"Our samples of Lipova-E200 have been under research and development by various firms, both domestic and internationally, especially those who are into sports nutrition,” said Patil.
She added that exports would be a key focus for VAV: "As far as India is concerned, consumers here prefer vegetable sources of protein over egg (sources), in spite of its clear benefits.
"For us, we are dedicated to promoting our products in the global market."
The first phase of the firm's new plant at Ratnagiri in Maharashtra is spread across 30,000 sq ft, with GMP-standard facilities.